Dose-Escalation Trial Protocols that Extend Naturally to Admit Titration

David C. Norris · 2025

Read Dose-Escalation Trial Protocols that Extend Naturally to Admit Titration by David C. Norris (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2507-01370.txt.

Introduction

David Norris argues, in 2025, that cancer dose trials should be designed so doses can later be adjusted for each patient. Most trials still seek one dose for all, based on toxicity limits in a sample. Efforts to individualize dosing appeared in the late nineteen nineties but stalled for many reasons.

Norris recasts trial rules in a category-based form built on an ordering of trial states. A valid protocol then becomes a map that respects that ordering, which encodes safety and treatment intent. The classic three-plus-three design is shown to hide a new flaw: a dose advice that breaks the ordering. A safe fix is sketched from the same framework.

Catalog record

CREATORDavid C. Norris
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE108 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2507-01370

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Dose-Escalation Trial Protocols that Extend Naturally to Admit Titration Thanks: Acknowledgments. Mark Thom’s Scryer Prolog, and the community that has grown around it, have made available a free, extensible, Standard-conforming Prolog system crucial for the computational aspects of this work. Markus Triska has illuminated Prolog for me from a modern standpoint, and continually provokes improvements in my code and my thinking. An anonymous reviewer generously dissected an earlier version of this work presented at the Eighth International Conference on Applied Category Theory. The remaining errors are mine. I dedicate this work to my father, and to the memory of my mother. David C. Norris Abstract . Dose-escalation trials in oncology drug development still today typically aim to identify 1-size-fits-all dose recommendations, as arbitrary quantiles of the toxicity thresholds evident in patient samples. In the late 1990’s efforts to individualize dosing emerged fleetingly in the oncology trial methods literature, but these have gained little traction due to a nexus of conceptual, technical, commercial, and regulatory barriers. To reduce the ‘activation energy’ needed for transforming current 1-size-fits-all dose-escalation trial designs to the dose- titration designs required for patient-centered dose individualization, we demonstrate a categorical formulation of dose-escalation protocols that extends readily to allow gradual introduction of dose titration. Central to this formulation is a symmetric monoidal preorder on the accessible states of dose-escalation trials, embodying pharmacologic intuitions regarding dose-monotonicity of drug toxicity and ethical intuitions relating to the therapeutic intent of such trials. A trial protocol that assigns doses to sequentially enrolled participants consistently with these intuitions is then a monotone map from this preorder to the ordered finite set of doses being trialed. We illustrate this formulation by reference to the ubiquitous ‘3+3’ dose-escalation design, which despite its many widely discussed flaws remains familiar to oncology trialists and moreover has available an executable specification in Prolog. Remarkably, examined in light of our preorder the 3+3 protocol discloses a new flaw not previously described: a non-monotone dose recommendation. The right Kan extension approximates this protocol from the side of safety, dissolving its 3-at-a-time cohorts to allow incremental enrollment, and perforce rectifying said non-monotonicity. It also facilitates accelerated enrollment while toxicity assessments remain pending, and indeed discretionary dose titration as well. A basic simulation experiment is presented, demonstrating the feasibility of trial protocols incorporating these elements, built on the right Kan extension as well as a strictly safer and more parsimoniously parametrized lower-Galois enrollment derived from it. Further efforts along these lines might aim to approximate any of several more modern dose-escalation designs that have begun to supplant the 3+3, or seek de novo designs with specified safety properties within the finite (if large) spaces of lower-Galois enrollment functors. 2020 Mathematics Subject Classification 92C50, 18B35, 18A40 1. Introduction Despite the long-recognized heterogeneity in patients’ pharmacokinetics and pharmacodynamics [ 1 ] , dose-finding trials in oncology still today generally aim to identify a 1-size-fits-all dose recommendation, in the form of an arbitrary quantile of the population distribution of toxicity thresholds [ 2 ] . While glimmers of hope have appeared fleetingly in the trial methods literature [ 3 , 4 ] , a complex interaction of conceptual, technical and political factors [ 5 , 6 , 7 ] has impeded progress toward dose individualization in oncology trials. Like an enzyme that reduces the activation energy needed for a chemical reaction, the present work aims to catalyze the transformation of existing dose-escalation designs to dose- titration designs. A categorical formulation yields a standpoint from which this transformation may be conceived and implemented naturally, instead of being regarded as a special or problematical case. 2. Operational Details of Dose-Escalation Trials In the methods literature, dose-finding designs are often defined and analyzed in highly stylized settings that abstract away certain essential operational details inherent to actual trials. Adapting such designs — often defined in terms of non-unit-sized ‘cohorts’ enrolled in discrete time — to continuous-time trial operations may be difficult. Grafting on such considerations after the fact may involve massive (yet still incomplete) protocol tabulations [ 8 , 9 ] . Here, however, we model these explicitly from the outset: In queueing-theory terms, a dose-finding protocol amounts to a service policy for an arrivals process in which patients who have cancer, after exhausting standard treatment options, express willingness to try an experimental treatment. At any time \tau , the protocol specifies a current enrolling dose [level] d(\tau)\in\{0,1,...,D\} indexing an increasing sequence of dose intensities \{0=x_{0}<x_{1}<...<x_{D}\} that were fixed ex ante . Patients arriving at a time \tau when d(\tau)=0 are placed into a waiting queue. While d(\tau)>0 any waiting patients are enrolled in order of arrival, 1 1 1 Since enrollment may generally update the current enrolling dose, preserving d(\tau) as a well-defined function of time requires that enrolling each individual from a non-empty waiting queue takes some nonzero time interval, albeit one that may be treated as effectively infinitesimal. and if the waiting queue is empty new arrivals are enrolled promptly. Notation 2.1 . The participants in a dose-escalation trial, indexed by i\in I , enroll at time \tau_{0}^{i} into dose level d^{i} . Given that toxic responses generally manifest with some latency after dose administration, toxicity assessment remains pending for participant i until some time \tau_{1}^{i}\in(\tau_{0}^{i},\tau_{0}^{i}+\delta\tau] when the assessment resolves into one of three outcomes : • Participant i is found to have experienced an (intolerable) toxicity , • to have become inevaluable due to early withdrawal from the trial or death unrelated to toxicity, • or otherwise (at \tau_{1}^{i}=\tau_{0}^{i}+\delta\tau ) is assessed to have tolerated their dose. 2 2 2 We here ignore late-manifesting toxicities that occur after the lapse of time \delta\tau , which is typically on the order of 1 month. Notation 2.2 . We indicate evaluability by n^{i}\in\{0,1\} , and occurrence of toxicity by y^{i}\in\{0,1\} or sometimes more distinctively by y^{i}\in\{\textup{{o}},\textup{{x}}\} . Notation 2.3 . We write I_{d}(\tau)\subseteq I for the subset of individuals enrolled at dose d whose assessments have resolved by time \tau : I_{d}(\tau)=\{i\in I\mid d^{i}=d,\,\tau_{1}^{i}\leq\tau\}. Definition 2.4 . For each dose d , we have at any time \tau the formal quotient, q_{d}(\tau)=\frac{t_{d}}{n_{d}}(\tau)=\sum_{i\in I_{d}(\tau)}\frac{y^{i}}{n^{i}}\;\in\;Q=\{t/n\mid t,n\in\mathbb{N};\;t\leq n\}, recording the assessment of t_{d} toxic responses among n_{d} evaluable trial participants who have received dose d . The vector of quotients q(\tau)=(q_{1},...,q_{D})(\tau)\in Q^{D} will be called the cumulative tally at time \tau . Together with the pending count p:\mathbb{R}^{+}\rightarrow\mathbb{N}^{D} having dosewise components p_{d}(\tau)=|\{i\in I\mid d^{i}=d,\,\tau_{0}^{i}\leq\tau<\tau_{1}^{i}\}|, this constitutes the enrolled state , s(\tau)=(q(\tau),p(\tau)) . Notation 2.5 . By implicitly regarding \tau as an arbitrary ‘current time’ or ‘now’, we will often freely suppress the \tau -dependence of I_{d} , q , p and s . In order to determine the enrolling dose d(\tau) as a function of s(\tau) , we proceed to elaborate a symmetric, monoidal partial order on Q^{D} that captures certain fundamental pharmacologic and ethical intuitions. 3. Modeling Pharmacologic Monotonicities Definition 3.1 . Let +:Q\times Q\rightarrow Q be defined by \frac{t_{1}}{n_{1}}+\frac{t_{2}}{n_{2}}=\frac{t_{1}+t_{2}}{n_{1}+n_{2}}. Observe that this is a monoidal operation with unit \frac{0}{0} , which extends in the obvious way to a monoidal operation on Q^{D} with unit (\frac{0}{0},...,\frac{0}{0}) . Definition 3.2 . Let \preceq be the transitive closure of a preorder relation satisfying, (1) \frac{t}{n}\!+\!\frac{1}{1}\;\preceq\;\frac{t}{n}\;\preceq\;\frac{t}{n}\!+\!\frac{0}{1}\quad\forall\;\frac{t}{n}\in Q. Then the preorder (Q,\preceq)

Read the complete text